Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure-two-year results from the HeartMate 3 CE Mark Study

JD. Schmitto, Y. Pya, D. Zimpfer, T. Krabatsch, J. Garbade, V. Rao, M. Morshuis, F. Beyersdorf, S. Marasco, P. Sood, L. Damme, I. Netuka,

. 2019 ; 21 (1) : 90-97. [pub] 20180727

Language English Country England, Great Britain

Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19028306

AIM: This study aimed to assess safety and outcomes of patients, 2 years after implantation with the HeartMate 3 Left Ventricular Assist System. METHODS AND RESULTS: This study included 50 adults with New York Heart Association (NYHA) class IIIB or IV symptoms or American College of Cardiology/American Heart Association stage D heart failure with an ejection fraction ≤25% and a cardiac index ≤2.2 L/min/m2 without inotropes, or inotrope-dependent with optimal medical management, or listed for heart transplant. The median duration of left ventricular assist device support was 694 days (range: 19-833 days). At baseline, cardiac index was 1.8 ±0.5 L/min/m2 , 58% of patients were receiving inotropes, and 92% were INTERMACS profiles 2-4. At 2 years, Kaplan-Meier survival was 74 ±6%, 5 (10%) patients were transplanted, and 32 patients (64%) remain with support. Adverse event rates include bleeding requiring surgery (16%), gastrointestinal bleeding (20%), driveline infection (24%), ischaemic stroke (16%), haemorrhagic stroke (8%), right heart failure (14%), and outflow graft thrombosis (2%). Notably, no haemolysis, pump thrombosis, or pump malfunction events occurred. At 2 years, 47% of patients remained in NYHA class I and 41% in NYHA class II (P <0.0001). From baseline to 2 years, the mean six-minute walk distance increased from 239 m to 347 m (P <0.0001), and the mean EQ-5D quality of life score improved from 48.2 to 70.6 (P < 0.0001). CONCLUSIONS: Two years post-HeartMate 3 implantation, results show expected and acceptable survival, enhanced haemocompatibility, improved patient functional status and quality of life. This corroborates the success of HeartMate 3 since its first-in-man implantation case in Germany. ClinicalTrials.gov: NCT02170363.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028306
003      
CZ-PrNML
005      
20190820090655.0
007      
ta
008      
190813s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ejhf.1284 $2 doi
035    __
$a (PubMed)30052304
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Schmitto, Jan D $u Hannover Medical School, Hannover, Germany.
245    10
$a Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure-two-year results from the HeartMate 3 CE Mark Study / $c JD. Schmitto, Y. Pya, D. Zimpfer, T. Krabatsch, J. Garbade, V. Rao, M. Morshuis, F. Beyersdorf, S. Marasco, P. Sood, L. Damme, I. Netuka,
520    9_
$a AIM: This study aimed to assess safety and outcomes of patients, 2 years after implantation with the HeartMate 3 Left Ventricular Assist System. METHODS AND RESULTS: This study included 50 adults with New York Heart Association (NYHA) class IIIB or IV symptoms or American College of Cardiology/American Heart Association stage D heart failure with an ejection fraction ≤25% and a cardiac index ≤2.2 L/min/m2 without inotropes, or inotrope-dependent with optimal medical management, or listed for heart transplant. The median duration of left ventricular assist device support was 694 days (range: 19-833 days). At baseline, cardiac index was 1.8 ±0.5 L/min/m2 , 58% of patients were receiving inotropes, and 92% were INTERMACS profiles 2-4. At 2 years, Kaplan-Meier survival was 74 ±6%, 5 (10%) patients were transplanted, and 32 patients (64%) remain with support. Adverse event rates include bleeding requiring surgery (16%), gastrointestinal bleeding (20%), driveline infection (24%), ischaemic stroke (16%), haemorrhagic stroke (8%), right heart failure (14%), and outflow graft thrombosis (2%). Notably, no haemolysis, pump thrombosis, or pump malfunction events occurred. At 2 years, 47% of patients remained in NYHA class I and 41% in NYHA class II (P <0.0001). From baseline to 2 years, the mean six-minute walk distance increased from 239 m to 347 m (P <0.0001), and the mean EQ-5D quality of life score improved from 48.2 to 70.6 (P < 0.0001). CONCLUSIONS: Two years post-HeartMate 3 implantation, results show expected and acceptable survival, enhanced haemocompatibility, improved patient functional status and quality of life. This corroborates the success of HeartMate 3 since its first-in-man implantation case in Germany. ClinicalTrials.gov: NCT02170363.
650    _2
$a design vybavení $7 D004867
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a srdeční selhání $x mortalita $x patofyziologie $x terapie $7 D006333
650    _2
$a srdeční komory $x patofyziologie $7 D006352
650    12
$a podpůrné srdeční systémy $7 D006353
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a tepový objem $x fyziologie $7 D013318
650    _2
$a míra přežití $x trendy $7 D015996
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Austrálie $x epidemiologie $7 D001315
651    _2
$a Kanada $x epidemiologie $7 D002170
651    _2
$a Evropa $x epidemiologie $7 D005060
651    _2
$a Kazachstán $x epidemiologie $7 D007623
651    _2
$a Spojené státy americké $x epidemiologie $7 D014481
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pya, Yuriy $u National Research Cardiac Surgery Center, Astana, Kazakhstan.
700    1_
$a Zimpfer, Daniel $u University of Vienna, Vienna, Austria.
700    1_
$a Krabatsch, Thomas $u German Heart Center, Berlin, Germany.
700    1_
$a Garbade, Jens $u Heart Center Leipzig, Leipzig, Germany.
700    1_
$a Rao, Vivek $u Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, Canada.
700    1_
$a Morshuis, Michiel $u Thoracic and Cardiovascular Surgery Clinic, Bad Oeynhausen, Germany.
700    1_
$a Beyersdorf, Friedhelm $u University Heart Center Freiburg-Bad Krozingen, Medical Faculty, Albert Ludwigs-University, Freiburg, Germany.
700    1_
$a Marasco, Silvana $u The Alfred Hospital, Melbourne, Australia.
700    1_
$a Sood, Poornima $u Abbott, Burlington, MA, USA.
700    1_
$a Damme, Laura $u Abbott, Burlington, MA, USA.
700    1_
$a Netuka, Ivan $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
773    0_
$w MED00006634 $t European journal of heart failure $x 1879-0844 $g Roč. 21, č. 1 (2019), s. 90-97
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30052304 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190820090930 $b ABA008
999    __
$a ok $b bmc $g 1433455 $s 1066766
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 21 $c 1 $d 90-97 $e 20180727 $i 1879-0844 $m European journal of heart failure $n Eur J Heart Fail $x MED00006634
LZP    __
$a Pubmed-20190813

Find record

Citation metrics

Archiving options